Leonor Arenillas

List of Publications by Year
in descending order

79	2,026	361045	243296
papers	citations	20 h-index	44 g-index

79	79	79	3184
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis. Leukemia Research, 2022, 112, 106771.	0.4	1
2	Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA. Blood Advances, 2022, 6, 3178-3188.	2.5	6
3	Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. EBioMedicine, 2022, 80, 104059.	2.7	7
4	Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. Blood Advances, 2022, 6, 3921-3931.	2.5	7
5	Circulating cellâ€free DNA improves the molecular characterisation of Phâ€negative myeloproliferative neoplasms. British Journal of Haematology, 2021, 192, 300-309.	1.2	13
6	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. Leukemia Research, 2021, 101, 106492.	0.4	0
7	Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, , 1.	1.4	1
8	Multiple TET2 Mutations As a New Biological Clue for Differentiating Oligomonocytic Chronic Myelomonocytic Leukemia from Myelodysplastic Syndromes. Blood, 2021, 138, 1530-1530.	0.6	0
9	Early Immune Profile Assessment By Flow Cytometry Predicts Severe COVID-19 Pneumonia. Blood, 2021, 138, 4197-4197.	0.6	0
10	Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 1533-1533.	0.6	0
11	Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes. Blood, 2021, 138, 2599-2599.	0.6	0
12	Clonal Dynamics of JAK2V617F and Non-Driver Mutations in Polycythemia Vera and Essential Thrombocythemia Patients Receiving Hydroxyurea Therapy. Blood, 2021, 138, 3623-3623.	0.6	1
13	Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes. Leukemia and Lymphoma, 2021, , 1-9.	0.6	0
14	Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. Blood Advances, 2020, 4, 5285-5296.	2.5	27
15	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica, 2019, 104, 778-788.	1.7	17
16	Non-del(5q) myelodysplastic syndromesâ€"associated loci detected by SNP-array genome-wide association meta-analysis. Blood Advances, 2019, 3, 3579-3589.	2.5	7
17	Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML) and Chronic Myelomonocytic Leukemia (CMML) Show Similar Clinical, Morphological, Immunophenotypic and Molecular Features. Blood, 2019, 134, 4266-4266.	0.6	1
18	Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation. Blood, 2019, 134, 2687-2687.	0.6	0

#	Article	IF	Citations
19	Clinical Interest of LMO2 Testing in Aggressive Large B-Cell Lymphomas. Blood, 2019, 134, 2899-2899.	0.6	0
20	High Diagnostic Utility of Flow Cytometry Based Peripheral Blood Monocyte Subset Analysis, CD56 and CD2 Expression in Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 5437-5437.	0.6	0
21	Generation of a New Prognostic Index for Chronic Myelomonocytic Leukemia (CMML) Based on Peripheral Blood Assessment. Blood, 2019, 134, 4262-4262.	0.6	0
22	(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes. Leukemia, 2018, 32, 1264-1266.	3.3	1
23	The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2. Haematologica, 2018, 103, 2008-2015.	1.7	19
24	Diagnostic Utility of Flow Cytometric Immunophenotyping in Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 5526-5526.	0.6	0
25	Immunophenotypic Characteristics of Olygomonocytic Chronic Myelomonocytic Leukemia Support Its Diagnosis As a Distinctive Entity in the Continuum of Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 5520-5520.	0.6	0
26	Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica, 2017, 102, 1099-1104.	1.7	81
27	Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. American Journal of Hematology, 2017, 92, E534-E541.	2.0	6
28	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSSâ€R). American Journal of Hematology, 2017, 92, 614-621.	2.0	12
29	Reply to M.A. Lichtman. Journal of Clinical Oncology, 2017, 35, 1376-1377.	0.8	0
30	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Modern Pathology, 2016, 29, 1541-1551.	2.9	11
31	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. Journal of Clinical Oncology, 2016, 34, 3284-3292.	0.8	20
32	Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category. Blood, 2016, 128, 3185-3185.	0.6	0
33	Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts. Blood, 2016, 128, 1991-1991.	0.6	0
34	Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia. Medicina ClÃnica (English Edition), 2015, 144, 487-490.	0.1	1
35	Fluorescencein situhybridization ofTP53for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 3183-3188.	0.6	2
36	Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?. PLoS ONE, 2015, 10, e0129375.	1.1	19

#	Article	IF	Citations
37	Myelodysplastic Syndromes (MDS) with Erythroid Hyperplasia: Enumerating Blasts from Non-Erythroid Cell Compartment Improves the Risk Stratification of MDS with Excess of Blasts. Blood, 2015, 126, 2894-2894.	0.6	0
38	The Complete Mutatome and Clonal Architecture of Del(5q). Blood, 2015, 126, 608-608.	0.6	1
39	RAEB-1 with Erythroid Hyperplasia and Erythroleukemia Share Clinico-Biological Features and Outcome: A Same Disease with Different Labels?. Blood, 2015, 126, 2866-2866.	0.6	0
40	Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry. Clinical Cancer Research, 2014, 20, 1007-1019.	3.2	44
41	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. Annals of Hematology, 2014, 93, 1695-1703.	0.8	25
42	Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. Blood, 2014, 124, 4659-4659.	0.6	0
43	Whole-Exome Sequencing in Myelodysplastic Syndromes with 5q Deletion. Blood, 2014, 124, 4635-4635.	0.6	0
44	Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype. Blood, 2014, 124, 3262-3262.	0.6	0
45	Myelodysplastic Syndromes with I(17)(q10) and Prognostic Implications of Mutations of TP53 and SETBP1. Blood, 2014, 124, 1910-1910.	0.6	0
46	Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome. Blood, 2014, 124, 4649-4649.	0.6	0
47	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leukemia Research, 2013, 37, 769-776.	0.4	11
48	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does â˜7/7qâ˜ detection by FISH have prognostic value?. Leukemia Research, 2013, 37, 416-421.	0.4	16
49	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica, 2013, 98, 1554-1562.	1.7	196
50	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British Journal of Haematology, 2013, 162, 74-86.	1.2	73
51	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes and Cancer, 2013, 52, 1167-1177.	1.5	44
52	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 2013, 121, 3005-3015.	0.6	251
53	Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica, 2013, 98, 568-575.	1.7	63
54	Whole-Exome Sequencing In Myelodysplastic Syndromes With 5q- and Normal Karyotype. Blood, 2013, 122, 1551-1551.	0.6	0

#	Article	IF	Citations
55	Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica, 2012, 97, 1036-1041.	1.7	79
56	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. British Journal of Haematology, 2012, 159, 311-321.	1.2	25
57	Multilineage Dysplasia Confers Poor Prognosis to Patients with De Novo Acute Myeloid Leukemia with Intermediate-Risk Cytogenetics and Wild-Type NPM1.. Blood, 2012, 120, 2551-2551.	0.6	0
58	Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. Spanish MDS Group (GESMD). Blood, 2012, 120, 3803-3803.	0.6	3
59	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood, 2011, 117, 4836-4843.	0.6	280
60	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica, 2011, 96, 996-1001.	1.7	100
61	Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array. Leukemia Research, 2011, 35, e161-e163.	0.4	2
62	Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?. Leukemia Research, 2010, 34, 1242-1245.	0.4	23
63	TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. Haematologica, 2010, 95, 1798-1800.	1.7	9
64	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leukemia and Lymphoma, 2010, 51, 1225-1232.	0.6	36
65	LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients. Blood, 2010, 116, 5054-5054.	0.6	1
66	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134.	0.6	0
67	Chronic Myelomonocytic Leukemia (CMML) with More Than 15% of Ring Sideroblasts in Bone Marrow: An Overlapping Disorder Between CMML and Refractory Anemia with Ring Sideroblasts.. Blood, 2009, 114, 290-290.	0.6	14
68	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	0.6	0
69	Blast cells with nuclear extrusions in the form of micronuclei are associated with MYC amplification in acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2008, 185, 32-36.	1.0	11
70	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	1.7	36
71	Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome. Blood, 2008, 112, 640-640.	0.6	73
72	No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 3615-3615.	0.6	5

#	Article	IF	Citations
73	Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.. Blood, 2008, 112, 1649-1649.	0.6	0
74	Gene Expression Profiling Distinguishes Essential Thrombocythemia from Polycythemia Vera Patients and Identifies a Common Expressed Set of Genes in Relation to JAK2V617F Status. Blood, 2008, 112, 2788-2788.	0.6	0
75	Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: Long-term outcome of 61 patients from a single institution. Leukemia and Lymphoma, 2007, 48, 1968-1975.	0.6	10
76	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. European Journal of Haematology, 2006, 76, 58-63.	1.1	36
77	Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma. Acta Haematologica, 2006, 116, 203-206.	0.7	12
78	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. Journal of Clinical Oncology, 2005, 23, 2797-2804.	0.8	253
79	Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine, 2004, 26, 145-148.	1.4	34